WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the “Class Period”), of the important September 8, 2025 lead plaintiff deadline.
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and six-month periods ended June 28, 2025.
Presentations showcased at World Transplant Congress in San Francisco demonstrate HOPE reduces the cost of liver transplantation by shortening the index hospitalization and decreasing...
Nonprofit health plan and Gemini Health deliver real-time notifications, allowing members to compare prescription drug prices, find lower-cost alternatives
OAKLAND, Calif., Aug. 6, 2025...
ARLINGTON, Va., Aug. 5, 2025 /PRNewswire/ -- This month, the American Diabetes Association® (ADA) celebrates 85 years of dedicated work toward its vision of...
Delivering Nutritious Meals Across Five Counties
TWIN FALLS, Idaho, Aug. 4, 2025 /PRNewswire/ -- Homestyle Direct is proud to announce its expansion into several new California...
Delivering Nutritious Meals for Eligible Medicaid Members in Erie and Allegheny Counties
TWIN FALLS, Idaho, Aug. 4, 2025 /PRNewswire/ -- Homestyle Direct is quickly becoming...
First-ever cross-border Green Medical Pass
Integrating resources from both regions for efficient access to healthcare services
HONG KONG, Aug. 4, 2025 /PRNewswire/ -- AXA Hong...
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies
CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India,...
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies
CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India,...
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies
CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India,...